An official website of the United States government
Home
Name
Akeega
Alternate Names
abiraterone acetate/niraparib
Abbreviations
None
Category
Chemotherapy
Subcategory
None
NSC Number
None
Primary Site
Prostate
Histology
None
Remarks
August 11, 2023 FDA approved the fixed dose combination of niraparib and abiraterone acetate (Akeega), with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved test.
Coding instructions: each dose is a combination of niraparib (chemotherapy agent) and abiraterone acetate (hormone) and prednisone (hormone). When given, code both chemotherapy and hormone.
Coding instructions: each dose is a combination of niraparib (chemotherapy agent) and abiraterone acetate (hormone) and prednisone (hormone). When given, code both chemotherapy and hormone.
Coding
Please see remarks for additional information
